Evidence map›Paper›PMID 39658411›Full record

ArticleScience bulletin2025

Purinergic signaling by TCRαβ

Hua Jin, Mingyang Li, Xiyu Wang, Lu Yang, Xinjie Zhong, Zihan Zhang, Xiaotong Han, Jingjing Zhu, Mengyi Li, Songlin Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. SLAMF7 promotes TCRαβJournal of experimental & clinical cancer research : CR · 2025
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hua JinImmunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Mingyang LiImmunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Xiyu WangMedical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Lu YangGeneral Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Xinjie ZhongMedical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Zihan ZhangImmunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Xiaotong HanMedical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Jingjing ZhuMedical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
Mengyi LiGeneral Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
Songlin WangBeijing Laboratory of Oral Health, Capital Medical University School of Basic Medicine, Beijing 100069, China.
Simon C RobsonCenter for Inflammation Research, Department of Anesthesia, Critical Care & Pain Medicine, and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA. Electronic address: srobson@bidmc.harvard.edu.
Guangyong SunImmunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address: sungy@ccmu.edu.cn.
Dong ZhangMedical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China; General Surgery Department, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; Beijing Laboratory of Oral Health, Capital Medical University School of Basic Medicine, Beijing 100069, China. Electronic address: zhangd@ccmu.edu.cn.

Funding

Immunomodulatory effects of bilirubin are mediated through aryl hydrocarbon receptor, O2 and purinergic pathwaysR01DK108894 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LONGHI, MARIA SERENA · 2017 to 2021
$2.0M
Purinergic ThromboregulationR01HL094400 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2009 to 2010
$1.4M
PGC-1α, Purines and the Postmenopausal HeartR21AG065923 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MATYAL, ROBINA, ROBSON, SIMON C. · 2021 to 2022
$481k
Directed Purinergic Signaling as Immunotherapy in LeukemiaR21CA221702 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI AVIGAN, DAVID E., ROBSON, SIMON C. · 2018 to 2019
$413k
Engineering Inhibitory Antibodies to Ectoenzymes for Cancer TreatmentR21CA164970 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ROBSON, SIMON C. · 2012 to 2013
$405k
Department of Defense W81XWH-16-0464NCI NIH HHS R21 CA164970NCI NIH HHS R21 CA221702NHLBI NIH HHS R01 HL094400NIA NIH HHS R21 AG065923NIDDK NIH HHS R01 DK108894
6 · The paper itself

Abstract

Hepatic ischemia-reperfusion injury (HIRI) is an important cause of liver injury following liver transplantation and major resections, and neutrophils are the key effector cells in HIRI. Double-negative T regulatory cells (DNT) are increasingly recognized as having critical regulatory functions in the immune system. Whether DNT expresses distinct immunoregulatory mechanisms to modulate neutrophils, as in HIRI, remains largely unknown. In this study, we found that murine and human DNT highly expressed CD39 that protected DNT from extracellular ATP-induced apoptosis and generated adenosine in tandem with CD73, to induce high levels of neutrophil apoptosis. Furthermore, extracellular adenosine enhanced DNT survival and suppressive function by upregulating survivin and NKG2D expression via the A2AR/pAKT/FOXO1 signaling pathway. Adoptive transfer of DNT ameliorated HIRI in mice through the inhibition of neutrophils in a CD39-dependent manner. Lastly, the adoptive transfer of A2ar

Indexed as

LiverReperfusion InjuryT-Lymphocytes, Regulatory5'-NucleotidaseAdenosineAdenosine TriphosphateAdoptive TransferAnimalsAntigens, CDApoptosisApyraseHumansMaleMiceMice, Inbred C57BLNeutrophils5'-NucleotidaseAdenosineAdenosine TriphosphateAntigens, CDApyraseCD39 antigenReceptor, Adenosine A2ASurvivinA2ARAdenosineCD39Double-negative T regulatory cellsHepatic ischemia and reperfusion injury

Identifiers

PMID39658411
PMCPMC11749161

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.